Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 2:40 AM ET


Company Overview of VentiRx Pharmaceuticals, Inc.

Company Overview

VentiRx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington.

1191 Second Avenue

Suite 1105

Seattle, WA 98101

United States

Founded in 2006





Key Executives for VentiRx Pharmaceuticals, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 52
Vice President of Finance and Administration
Chief Operating Officer
Chief Medical Officer
Vice President of Research
Compensation as of Fiscal Year 2015.

VentiRx Pharmaceuticals, Inc. Key Developments

VentiRx Pharmaceuticals, Inc. Announces Fast Track Designation Granted for Motolimod (VTX-2337)

VentiRx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of motolimod (VTX-2337) when administered in combination with pegylated liposomal doxorubicin (PLD) for the treatment of women with ovarian cancer whose disease has progressed on or recurred after platinum-based chemotherapy. Motolimid is a novel TLR8 immunotherapy currently being evaluated in two randomized, placebo-controlled Phase 2 trials. FDA Fast Track Designation is designed to facilitate frequent interactions with the FDA review team to expedite clinical development and submission of a New Drug Application (NDA) for drugs with the potential to treat serious or life-threatening conditions and address unmet medical needs. VentiRx has completed enrollment of over 290 patients in the GOG-3003 randomized, placebo-controlled Phase 2 trial of motolimod in combination with PLD in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior platinum-based chemotherapy. The study is being performed in collaboration with the Gynecologic Oncology Group (GOG) Partners Program. The primary endpoint of the study is overall survival. In April 2014, the FDA granted Orphan Drug designation to motolimod (VTX- 2337) for the treatment of ovarian cancer.

VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM

VentiRx Pharmaceuticals, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-19-2014 10:45 AM. Venue: Washington State Convention Center, Seattle, Washington, United States.

VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM

VentiRx Pharmaceuticals, Inc. Presents at Boston CEO Conference, Jun-05-2014 09:30 AM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: Robert M. Hershberg, Co-Founder, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Trinity Therapeutics, Inc. United States
Argus Health Products, LLC United States
Mitsubishi Pharma America, Inc. United States
Axiom Laboratories, LLC United States
BPR Health International, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VentiRx Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at